Table 1 Baseline characteristics of patients
Characteristics | Number of patients (n = 216) |
|---|---|
Gender, M/F (%male) | 123/93 (56.9) |
Age (yrs) (mean ± SD) * | 53.6 ± 9.0 |
Initial Weight (Kg) (mean ± SD)* | 76.4 ± 14.0 |
BMI (Kg/m2) (mean ± SD)* | 27.5 ± 4.7 |
Median Aminotrasferase levels. U/L (range)** | Â |
  Baseline Alanine aminotrasferase (ALT) | 95 (61–165) |
  Baseline Aspartate aminotransferase (AST) | 84.5 (52–123) |
HCV Genotype, n (%) | n = 216 |
  Genotype 2 | 12 (5.6) |
  Genotype 3 | 204 (94.4) |
Response to previous treatment, n (%) | n = 216 |
  Non-responders | 128 (59.3) |
  Relapsers | 88 (40.7) |
Histological diagnosis, n (%)*** | n = 196 |
  Fibrosis stage 0 – 2 | 47 (24.0) |
  Fibrosis stage 3 – 4 | 149 (76.0) |
Baseline serum HCV RNA (IU/mL), n (%)**** | n = 155 |
  < 800.000 | 55 (35.5) |
  ≥ 800.000 | 100 (64.5) |